The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-26), vTv Therapeutics's share price is €30.80. vTv Therapeutics's Book Value per Share for the quarter that ended in Mar. 2026 was €19.76. Hence, vTv Therapeutics's PB Ratio of today is 1.56.
The historical rank and industry rank for vTv Therapeutics's PB Ratio or its related term are showing as below:
FRA:5VT0'
s PB Ratio Range Over the Past 10 Years
Min: 1.13 Med: 2.54 Max: 21.21
Current: 1.63
During the past 13 years, vTv Therapeutics's highest PB Ratio was 21.21. The lowest was 1.13. And the median was 2.54.
FRA:5VT0's PB Ratio is ranked better than 69.32% of 1232
companies
in the Biotechnology industry
Industry Median: 2.8
vs FRA:5VT0: 1.63
During the past 12 months, vTv Therapeutics's average Book Value Per Share Growth Rate was 653.20% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of vTv Therapeutics was 67.10% per year. The lowest was -26.10% per year. And the median was 45.65% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
vTv Therapeutics PB Ratio Related Terms
vTv Therapeutics PB Ratio Historical Data
* Premium members only.
The historical data trend for vTv Therapeutics's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, vTv Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
vTv Therapeutics PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, vTv Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where vTv Therapeutics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
vTv Therapeutics (FRA:5VT0) has a PB Ratio of 1.56 as of Jun. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on vTv Therapeutics and its competitors. This is 39% below median its historical median of 2.54. Over the past decade, vTv Therapeutics' PB Ratio has ranged from 1.13 to 21.21. According to the industry distribution chart, vTv Therapeutics ranks #378 out of 1232 companies in the Biotechnology industry, placing it in the top 30.7%.
Is vTv Therapeutics' PB Ratio too high?
vTv Therapeutics' current PB Ratio of 1.56 is 39% below median its 10-year median of 2.54. Over the past 10 years, this metric has ranged from a low of 1.13 to a high of 21.21. The Biotechnology industry median PB Ratio is 2.80. vTv Therapeutics' value of 1.56 is 44.3% below this industry median. Based on the distribution chart, vTv Therapeutics ranks #378 out of 1232 companies in the Biotechnology industry, which is above the industry midpoint. Overall, vTv Therapeutics has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does vTv Therapeutics' PB Ratio compare to CRDF and GUTS?
According to the Biotechnology industry distribution chart, vTv Therapeutics ranks #378 out of 1232 companies for PB Ratio. This puts vTv Therapeutics in the upper half of its industry. The industry median PB Ratio is 2.80. vTv Therapeutics' value of 1.56 is 44.3% below this benchmark. Historically, vTv Therapeutics' own PB Ratio has ranged from 1.13 to 21.21 over the past decade. While the company's 10-year median is 2.54 vs. the industry median of 2.80, vTv Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,232 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. vTv Therapeutics's current PB Ratio of 1.56 is 44.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on vTv Therapeutics and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. vTv Therapeutics's current PB Ratio is 1.56, which is 39% below median its own 10-year median of 2.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is vTv Therapeutics stock overvalued right now?
vTv Therapeutics (FRA:5VT0) has a current PB Ratio of 1.56. The stock's GF Value™ is €6,491.15, compared to a current price of €30.80 — trading 99.5% below its estimated fair value. The current PB Ratio is 1.56, which is 39% below median its 10-year median of 2.54 and 44.3% below the Biotechnology industry median of 2.80. vTv Therapeutics' overall GF Score™ is 35/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For vTv Therapeutics (FRA:5VT0), the current PB Ratio is 1.56 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is vTv Therapeutics (FRA:5VT0) Overvalued in 2026?
Based on GuruFocus' analysis, vTv Therapeutics stock appears to be undervalued.
The current stock price of €30.80 is trading 99.5% below its estimated GF Value™ of €6,491.15.
Key valuation signals for FRA:5VT0:
PB Ratio: 1.56 (39% below median its 10-year median of 2.54)
GF Value™: €6,491.15 vs. price of €30.80 (99.5% below fair value)
Industry Position: 44.3% below the Biotechnology median (#378 of 1232)
No single metric tells the full story. See the FRA:5VT0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.
35GF Score
Get the complete analysis for FRA:5VT0
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:5VT0 has been successfully added to your 
